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A B S T R A C T 
Objectives: To compare the PathVysion fluorescence 
in-situ hybridisation assay with the INFORM 
HER2 Dual in-situ hybridisation assay on 104 
invasive breast cancers with a broad spectrum of 
immunohistochemistry scores.
Methods: This case series involved consecutive 
patients diagnosed with invasive breast carcinoma 
with equivocal immunohistochemistry score and 
referred for further HER2 assessment from the 
departments of Surgery and/or Clinical Oncology 
of the two hospitals between January 2013 and 
February 2014. An additional 10 cases with negative 
HER2 immunohistochemistry and 11 cases with 
positive HER2 immunohistochemistry were further 
included. 
Results: The results of both fluorescence in-situ 
hybridisation and dual in-situ hybridisation were 
available in 99 of 104 cases, respectively. Student’s 
t test showed no statistically significant difference 
in the mean number of HER2 count, CEP17 copies, 
or HER2/CEP17 ratio between that obtained 
by fluorescence in-situ hybridisation and that 
obtained by dual in-situ hybridisation. Pearson’s 
correlation of results for the two assays was strong 
for HER2/CEP17 signal ratio (R=0.963, P<0.001) 
and mean HER2 copies per nucleus (R=0.897, 
P<0.001). Overall agreement was 96.0% (95 out 
of 99 cases, ĸ=0.882). Three of the four discordant 
cases were equivocal for either fluorescence in-situ 
hybridisation or dual in-situ hybridisation. The 
Comparison of fluorescence in-situ hybridisation 
with dual-colour in-situ hybridisation for 
assessment of HER2 gene amplification of breast 
cancer in Hong Kong
Introduction
Breast cancer is the most common female 
malignancy. In Hong Kong, breast cancer accounted 
for about 26% of newly diagnosed cancers and 10% of 
cancer mortality in women.1 The human epidermal 
New knowledge added by this study
• Our local experience confirmed the diagnostic value of dual in-situ hybridisation (DISH) for assessment of 
HER2 gene amplification in breast cancer, with excellent correlation between fluorescence in-situ hybridisation 
assay (FISH) and DISH results. Cases that failed FISH were successful with DISH and vice versa.
Implications for clinical practice or policy
• DISH provides a reliable and useful option for HER2 testing in breast cancer, and offers some practical 
advantages.
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growth factor receptor type 2 (HER2) gene is a very 
important predictor of clinical outcome in breast 
cancer patients; protein overexpression or gene 
amplification is associated with higher rates of 
recurrence and higher mortality,2 and responsiveness 
ORIGINAL ARTICLE
results of immunohistochemistry 0/1+ and 3+ 
cases showed 100% concordance between the two 
assays. The failure rate was 0.96% for fluorescence 
in-situ hybridisation and 3.85% for dual in-situ 
hybridisation. Cases that failed for fluorescence 
in-situ hybridisation were successful for dual in-situ 
hybridisation and vice versa.
Conclusions: Our study showed that dual in-situ 
hybridisation is a reliable and useful option for HER2 
testing in breast cancer.
#  HER2 gene amplification of breast cancer  # 
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熒光原位雜交技術與雙色原位雜交技術檢測香港
乳癌HER2狀態的比較
鄧文俊、宋崧、陸美儀、孫杜琪、丘斐、萬佩心、秦家麗、 
邱瑋璇
目的：在104個涵蓋不同免疫組織化學分析評分結果的侵犯性乳癌
個案樣本上比較PathVysion熒光原位雜交技術（FISH）和INFORM 
HER2雙色原位雜交技術（DISH）。
方法：這項病例系列研究納入2013年1月至2014年2月期間，所有免
疫組織化學結果顯示模棱兩可的侵犯性乳癌個案樣本而被轉介至香港
兩所公立醫院的病理學、外科和臨床腫瘤科部門作進一步HER2基因
評估的個案樣本，以及10個陰性免疫組織化學分析結果和11個陽性免
疫組織化學分析結果的樣本。
結果：104個樣本當中，有99個成功取得FISH和DISH結果作比較。
使用兩個方法得出的平均HER2數目、CEP17標記數量和HER2/
CEP17比例並沒有顯著差異。HER2/CEP17比例（R=0.963，
P<0.001）和每個細胞核的平均HER2數目的Pearson相關系數
（R=0.897，P<0.001）均呈強線性關係。兩項技術的結果整體一致
率為96.0%（99個樣本中有95個結果相同，ĸ=0.882)。在測試結果不
一致的4個樣本當中，有3個在FISH或DISH其中一種技術得出模梭兩
可的結果。免疫組織化學結果顯示0/1+和3+的樣本利用這兩種技術的
化驗結果完全一致。不能成功進行FISH及DISH檢測的失敗率分別是
0.96%及3.85%。所有不能進行FISH檢測的個案皆可成功通過DISH檢
測並獲得結果，反之亦然。
結論：DISH是偵測乳癌HER2一個可靠和有用的測試方法。
to endocrine3 and chemotherapeutic regimens.4 
Trastuzumab (Herceptin; Genentech Inc, South San 
Francisco, US) that targets the HER2 oncoprotein 
is an established therapy for HER2-positive breast 
cancer patients in both the adjuvant5,6 and metastatic 
settings.7,8 Thus HER2 status is an important guide to 
the use of systemic adjuvant therapies. Because of the 
expense and potential life-threatening cardiotoxicity 
of Herceptin therapy, accuracy of the HER2 testing is 
of primary importance.
 The American Society of Clinical Oncology 
and the College of American Pathologists (ASCO/
CAP) have issued guidelines recommending 
determination of HER2 status in all patients with 
invasive breast cancer (early stage, or recurrence/
metastasis) to guide therapy.9-11 Following the 
guidelines published in 2007, many laboratories now 
use immunohistochemistry (IHC) as a screening 
test, with fluorescence in-situ hybridisation (FISH) 
used to determine HER2 status in equivocal IHC 
cases and to serve as a reference standard. The 
prevalence of HER2 gene amplification in breast 
cancer varies between studies, ranging from about 
20% to 30%.10,12-15
 Although FISH remains the ‘gold standard’ to 
determine HER2 gene amplification, in 2013, the 
INFORM HER2 Dual-ISH DNA Probe Cocktail 
assay (Ventana Medical Systems, Tucson, US) was 
approved by the Food and Drug Administration 
(FDA) for determination of HER2 gene amplification 
status as an alternative to FISH.16 It utilises silver 
in-situ hybridisation (ISH) to detect the HER2 
gene and chromogenic ISH for the chromosome 
17 centromere (CEP17) for visualisation on the 
same slide under light microscopy. Both FISH 
and dual-colour in-situ hybridisation (DISH) use 
formalin-fixed, paraffin-embedded breast cancer 
tissue specimens, but DISH has the advantage of 
allowing light microscopy assessment. This enables 
concurrent visualisation of histomorphological 
features with HER2 gene status, permitting the 
invasive component of the tumour to be more 
easily identified and analysed. Unlike FISH where 
the immunofluorescent signals will fade, DISH 
specimens can be archived and retrieved indefinitely. 
The assay can be processed on an automated platform 
and can contribute to reduced reporting turnaround 
time.
 Some studies that compared FISH and DISH 
assays have shown excellent concordance.17-20 
We have previously reported the prevalence and 
concordance between IHC HER2 overexpression 
and ISH assay of breast cancers in Hong Kong.21 
Funded by the SK Yee Medical Foundation to provide 
HER2 FISH testing in patients receiving treatment 
from public hospitals, and with subsequent FDA 
approval to provide the alternative HER2 DISH test, 
we performed a validation study in our laboratory 
to compare the results of FISH and DISH tests in 
determining HER2 status in breast cancer, before 
offering DISH for routine testing.
Methods
Patients 
This retrospective study included 104 breast cancer 
cases referred from the Department of Clinical 
Oncology of Pamela Youde Nethersole Eastern 
Hospital and Queen Mary Hospital, and from the 
Department of Surgery, Queen Mary Hospital. Case 
selection was based on IHC results representing 
three IHC categories: negative (0 or 1+ HER2 score), 
equivocal (2+ HER2 score), and positive (3+ HER2 
score) for HER2 overexpression, interpreted and 
classified according to the ASCO/CAP guidelines 
at the time of presentation. Slides from both 
hospitals were reviewed and confirmed to fulfil the 
updated classification score of the ASCO/CAP 2013 
guidelines. These included 83 consecutive cases 
between January 2013 and February 2014 that were 
equivocal for HER2 IHC (2+ score). In addition, 10 
cases that were reported to be HER2 IHC-negative 
(0 or 1+ score) and 11 cases reported as HER2 IHC-
positive (3+ score) were added to the study.
  #  Tang et al #
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 All patients had undergone surgery for invasive 
breast cancer. None had received preoperative 
chemotherapy. All tests were performed at the CAP-
accredited University Pathology Laboratory of the 
University of Hong Kong.
 Serial 4-6 µm sections were prepared from 
formalin-fixed, paraffin-embedded tumour tissue. 
Sections were sent for haematoxylin and eosin 
(H&E) and immunohistochemical staining. The H&E 
sections were reviewed by a certified pathologist. 
Areas of invasive tumour were marked on the slide 
for assessment. For FISH analysis, only the invasive 
tumour components were included for assessment, 
being mindful that it is difficult to distinguish in-situ 
from invasive carcinoma under assessment by dark 
field imaging.
Fluorescence in-situ hybridisation analysis
The FISH testing was performed using the FDA-
approved PathVysion HER2 DNA Probe Kit (Abbott 
Molecular Inc, Illinois, US). All samples were 
processed following previously defined protocols in 
compliance with the manufacturer’s instructions. 
Briefly, the slides were baked overnight at 56°C, 
deparaffinised, dehydrated, and air-dried. This was 
followed by protease treatment for 30 minutes. DNA 
was denatured at 72°C and hybridisation carried out 
at 37°C for 16 hours.
 Slides were then washed and air-dried. 
Counterstain was applied and the slide covered and 
sealed. Positive and negative controls were included 
for each batch of analysis. Slides were then visualised 
under a fluorescence microscope (CGH workstation, 
FIG 1.  FISH and DISH results of two representative cases
(a) FISH result of case #34 with a signal ratio of 1.22 (non-amplified). (b) DISH result of the same patient with a signal ratio of 1.45 
(non-amplified). (c) FISH result of case #1 with a signal ratio of 4.4 (amplified). (d) DISH result of the same patient with a signal 
ratio of 4.97 (amplified)
Abbreviations: DISH = dual-colour in-situ hybridisation; FISH = fluorescence in-situ hybridisation
(a)
(c)
(b)
(d)
#  HER2 gene amplification of breast cancer  # 
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Leica Q550CW) with a 100x objective using a triple 
filter that included DAPI, GFP, and Texas Red. The 
HER2 gene is visualised as a red/orange signal, and 
the CEP17 as a green signal.
 The number of HER2 and CEP17 signals was 
counted for 20 nuclei. The signal ratio was then 
calculated for each case. One to three photos were 
taken for each case. Following criteria given by the 
ASCO/CAP guidelines, a FISH result was rejected 
and repeated if: controls were not as expected; 
observer could not find and count at least two areas 
of invasive tumour; >25% of signals were unscorable 
due to weak signals; >10% of signals occurred 
over cytoplasm; nuclear resolution was poor; or 
autofluorescence was strong.9 Figures 1a and 1c 
show representative FISH results of a sample from 
two patients.
Dual-colour in-situ hybridisation analysis
The DISH testing was performed using the INFORM 
HER2 Dual-ISH DNA Probe Cocktail assay (Ventana 
Medical Systems, Tucson, US). All samples were 
processed automatically by BenchMark XT (Ventana 
Medical Systems). The HER2 was detected by a 
dinitrophenyl (DNP)–labelled probe and visualised 
in black colour utilising the ultraView Silver ISH 
DNP Detection Kit (Ventana Medical Systems). 
The CEP17 was targeted with a digoxigenin 
(DIG)–labelled probe and detected as a red signal 
using the ultraView Red ISH DIG Detection Kit 
(Ventana Medical Systems). Haematoxylin II 
was used as counterstain. Positive and negative 
controls were included for each batch of analysis. 
Slides were visualised under a 40x objective with a 
light microscope. Signal counting was performed 
according to the manufacturer’s interpretation 
guide. The number of HER2 and CEP17 signals was 
counted for 20 nuclei and the signal ratio calculated 
for each case. One to three photos were taken for 
each slide. A DISH result was rejected and repeated 
according to the same criteria as FISH in the ASCO/
CAP guidelines. Figures 1b and 1d show the DISH 
results for the same two patients in Figures 1a and 1c.
Scoring criteria
For signal counting of FISH and DISH, the number 
of HER2 gene signals and CEP17 signals were 
counted in 20 tumour nuclei. The HER2/CEP17 
signal ratio and mean number of HER2 signals per 
nucleus was calculated. HER2 gene amplification 
status was then determined according to ASCO/
CAP 2013 guidelines for dual-probe ISH assay.9 For 
cases that presented before the 2013 guidelines, raw 
data of signal enumeration were retrieved, and the 
results reclassified after applying the new guideline. 
Briefly, if HER2/CEP17 ratio was ≥2.0, it was 
classified as positive. If HER2/CEP17 ratio was <2.0, 
classification would be based on mean HER2 copy 
number per nucleus. If mean HER2 copy number 
per nucleus was ≥6, then it was positive; if it was ≥4.0 
and <6.0, then it was equivocal; if it was <4.0, then it 
was negative.
Statistical analyses
Cases that failed FISH or DISH analysis were 
excluded from statistical analysis. The Statistical 
Package for the Social Sciences (Windows version 
20.0; SPSS Inc, Chicago [IL], US) was used. The 
following statistical analyses were performed:
(1) First, one-way analysis of variance (ANOVA) 
test was used to analyse the relationship 
between IHC result and quantitative results of 
FISH and DISH.
(2) We tested whether DISH underestimated or 
overestimated the number of HER2 or CEP17 
copies when compared with FISH. The null 
hypothesis was that there was no difference. 
Student’s t test was used to examine the result 
of both tests on mean HER2/CEP17 ratio 
and mean HER2 copy number per nucleus. 
A P value of <0.05 indicated a statistically 
significant difference.
(3) We also used the Bland-Altman plots to show 
the degree of agreement graphically. Linear 
regression was used to show the relationship 
of FISH and DISH results. Pearson product-
moment correlation coefficient (R) was 
calculated to evaluate the correlation between 
quantitative results of FISH and DISH. A 
positive R (0 to 1) indicates positive correlation 
and a negative R indicates negative correlation. 
If -1≤R<-0.7 or 0.7<R≤1, it indicates strong 
association. A P value of <0.05 indicated a 
statistically significant difference.
(4) To evaluate agreement between FISH and 
DISH in the classification of HER2 gene 
amplification status, Cohen’s Kappa coefficient 
was used to factor in the possibility that the two 
tests agreed due to chance. We also calculated 
simple agreement percentage for comparison 
with results of other studies.
 All tests were two-sided. All confidence 
intervals (CIs) and P values were included in the 
results.
Results
Failure cases
Both FISH and DISH results were available in 99 of 
104 cases. One case (#85) failed FISH analysis after 
two attempts. Four cases (#14, #78, #84, #101) failed 
DISH analysis after two attempts. The failure rate 
was 0.96% for FISH and 3.85% for DISH. The reasons 
for failure included criteria for result rejection as 
stated in ASCO/CAP guidelines.
  #  Tang et al #
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One-way analysis of variance
The results of one-way ANOVA analysis are shown 
in Table 1. For FISH versus IHC, the P value was 
<0.001 for mean HER2/CEP17 ratio and mean HER2 
copies per nucleus. Both were <0.05, indicating a 
significantly different FISH reading for the different 
IHC groups. For DISH versus IHC, the P value was 
<0.001 for mean HER2/CEP17 ratio and mean HER2 
copies per nucleus. Both were <0.05, indicating a 
significantly different DISH reading for the different 
IHC groups.
Student’s t test
The result of Student’s t test is shown in Table 2. The 
mean number (± standard deviation) of HER2 counts 
by FISH analysis was 3.5 ± 2.8, result by DISH was 
3.8 ± 3.0 with no statistically significant difference 
between the results (P=0.41). The mean HER2/CEP17 
ratio by FISH was 2.1 ± 2.1, result by DISH was 
2.1 ± 1.8. There was no statistically significant 
difference between the results (P=0.86).
Bland-Altman (limits of agreement) plot
The Bland-Altman plot is shown in Figure 2a. For 
HER2 counts per nucleus, the mean difference 
(FISH-DISH) was 0.386. The 95% CI was -2.99 to 
2.22. For HER2/CEP17 ratio, the mean difference 
(FISH-DISH) was 0.279. The 95% CI was -0.87 to 
1.43.
Linear regression and Pearson’s correlation 
between the two in-situ hybridisation assays
Scatter diagrams of DISH plotted against FISH 
results are shown in Figure 2b. Linear regression 
showed that DISH resulted in a lower HER2/CEP17 
ratio than FISH, the tendency being more obvious at 
a higher ratio. Pearson’s correlation coefficient was 
0.897 (95% CI, 0.84-0.95, P<0.001) for mean HER2 
copies per nucleus and 0.963 (95% CI, 0.95-0.98, 
P<0.001) for HER2/CEP17 ratio. This indicated the 
correlation was excellent.
Kappa’s agreement between amplification 
status results by the two in-situ hybridisation 
assays
The result of amplification status by DISH and FISH 
is shown in Table 3. Overall agreement of FISH and 
DISH was 96.0% (95 out of 99 cases), and Cohen’s 
Kappa coefficient was 0.882 (95% CI, 0.77-0.99, 
P<0.001), which indicates good agreement. Results 
for IHC 0/1+ and 3+ cases showed 100% concordance 
between FISH and DISH. All discordant cases 
belonged to the IHC 2+ category and details of the 
cases are shown in Table 4. It is interesting to note 
that three of these four discordant cases were in the 
equivocal category for either FISH or DISH.
Discussion
It is important to develop an accurate test for 
HER2 status in breast cancer so that patients can 
receive optimal treatment. A false-negative result 
may lead to delay or omission of HER2 targeting 
treatment. A false-positive one, however, may result 
in unnecessary treatment for the patient. This is 
particularly important because HER2 targeting 
drugs are known to cause rare but significant 
adverse effects, including serious cardiotoxicity.10 In 
addition, the cost of treatment is high and may be a 
financial burden for patients.
Abbreviations: ANOVA = analysis of variance; DISH = dual-colour in-situ hybridisation; 
FISH = fluorescence in-situ hybridisation; IHC = immunohistochemistry; ISH = in-situ 
hybridisation; SD = standard deviation
Abbreviations: DISH = dual-colour in-situ hybridisation; FISH = fluorescence in-situ 
hybridisation
* Overall agreement = 96.0% (95 out of 99 cases), and Cohen’s Kappa coefficient was 
0.882 (95% confidence interval, 0.77-0.99, P<0.001)
Abbreviations: DISH = dual-colour in-situ hybridisation; FISH = fluorescence in-situ 
hybridisation; N/A = not applicable; SD = standard deviation
TABLE 1.  ANOVA analysis of IHC and ISH results
TABLE 3.  Comparison of amplification status results by FISH and DISH*
TABLE 2.  Comparison of HER2 and CEP17 counts and HER2/CEP17 ratio by FISH 
and DISH
FISH and DISH results IHC results (mean ± SD) P value
0/1+ 2+ 3+
FISH
HER2/CEP17 ratio 1.29 ± 0.10 1.83 ± 1.83 5.12 ± 2.45 <0.001
HER2 copies per nucleus 1.98 ± 0.39 3.02 ± 2.26 8.03 ± 3.46 <0.001
DISH
HER2/CEP17 ratio 1.42 ± 0.28 1.83 ± 1.64 4.73 ± 2.22 <0.001
HER2 copies per nucleus 2.46 ± 0.43 3.34 ± 2.36 8.85 ± 4.14 <0.001
FISH DISH Total
Amplified Equivocal Non-amplified
Amplified 18 0 0 18
Equivocal 0 1 1 (Case #8) 2
Non-amplified 1 (Case #83) 2 (Cases #13, 26) 76 79
Total 19 3 77 99
Counts/ratio Mean ± SD (range) P value
FISH DISH
HER2 counts (20 cells) 69.2 ± 56.1 (25-333) 76.0 ± 59.8 (28-277) N/A
HER2 counts per nucleus 3.5 ± 2.8 (1.3-16.7) 3.8 ± 3.0 (1.4-13.9) 0.41
CEP17 counts (20 cells) 34.5 ± 9.8 (20-68) 38.3 ± 13.1 (20-102) N/A
HER2/CEP17 ratio 2.1 ± 2.1 (1.1-14.5) 2.1 ± 1.8 (1.05-11.0) 0.86
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 Various methods have been developed 
for HER2 testing. The ASCO/CAP guidelines 
recommend HER2 testing by IHC and ISH methods. 
Each has their own advantages and disadvantages.
 The advantages of IHC include its high 
specificity, relatively low price, and short turnaround 
time. Further, the immunostain does not degrade over 
time. Its sensitivity is variable, however, and affected 
significantly by pre-analytic, analytic, and post-
analytic factors.2,11,22 Tissue fixation factors, such 
FIG 2.  (a) Bland-Altman plots illustrating limits of agreement. The difference between each paired measurement (FISH-DISH) is plotted against the 
mean of the paired measurements. (b) Scatter diagrams illustrating correlation of DISH results with FISH results
Abbreviations: CI = confidence interval; DISH = dual-colour in-situ hybridisation; FISH = fluorescence in-situ hybridisation
(i) Bland-Altman plot for HER2 counts per nucleus. The mean 
difference (FISH-DISH) is 0.386; lowest line shows slightly higher 
bias with FISH, with greater discrepancy between FISH and DISH at 
higher HER2 counts; 95% CI, -2.99 to 2.22 (dotted lines)
(ii) Bland-Altman plot for HER2/CEP17 ratio. The mean difference 
(FISH-DISH) is 0.279; lowest line shows slightly higher bias with 
FISH for the majority for cases; 95% CI, -0.87 to 1.43 (dotted lines)
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(i) Scatter plot for HER2 counts per nucleus for FISH and DISH. 
Dotted line is the line of equality (perfect concordance). Solid 
line represents linear regression, y = 0.965x + 0.506, R2 = 0.804, 
P<0.001; Pearson’s correlation coefficient = 0.897, P<0.001
(ii) Scatter plot for HER2/CEP17 ratio for FISH and DISH. Dotted line 
is the line of equality (perfect concordance). Solid line represents 
linear regression, and shows DISH results in lower estimates for 
HER2/CEP17 ratios than FISH, y = 0.852x + 0.286, R2 = 0.927, 
P<0.001; Pearson’s correlation coefficient = 0.963, P<0.001
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as ethanol exposure and antigen retrieval methods, 
can lead to inaccurate IHC results.11 In an ideal 
setting, tissue for IHC should be fixed in 10% neutral 
buffered formalin for 6 to 48 hours,9 but in practice 
it is not uncommon for insufficient formalin to be 
used or for time-to-fixation to be often prolonged.11 
There may also be scoring error. Although the use 
of controls can reduce interobserver variability, it 
cannot be eliminated.22
 The general advantage of ISH methods 
compared with IHC is that ISH may be accurately 
performed on tissues fixed for variable lengths of 
time and in other fixatives.11 In addition, ISH can 
also be applied to a wide range of tissue samples, 
such as paraffin-embedded tissue, frozen samples, 
or micro-tissue arrays.2 Nonetheless, the different 
types of ISH also have their respective shortcomings.
 The disadvantage for FISH is that, first, it 
is not possible to identify cell morphology and 
other histological features because it is visualised 
under fluorescence microscopy. Second, since the 
fluorescence of the probe will decay with time, 
samples cannot be archived.2 This makes it difficult 
for future retrieval and for re-examination. Third, 
sample preparation is complex and usually takes at 
least 2 days.
 On the other hand, DISH makes use of bright-
field microscopy that allows better delineation of 
cell morphology, tumour heterogeneity, and easier 
identification of tumour cells.2 Also, automation 
is possible so complexity and time required for 
sample preparation can be reduced. The DISH assay, 
however, is not perfect. One of its disadvantages is 
that analysis may sometimes fail. In our experience, 
the failure rate for DISH is somewhat higher than 
that for FISH. To date, there remain few studies 
published on the accuracy of DISH compared with 
FISH or IHC.17-20 
 This study provides more information 
about concordance of DISH and FISH, and is the 
first report from Hong Kong. In our study, FISH 
and DISH showed no statistical difference for 
HER2/CEP17 ratio and HER2 counts per nucleus. 
Correlation between the values was high. Pearson’s 
correlation coefficient in our study was 0.963 for 
HER2/CEP17 ratio, and 0.897 for mean HER2 copies 
per nucleus. This is similar to the values reported by 
other studies, ranging from 0.79 to 0.81 by Gao et 
al17 and 0.85 to 0.87 by Horii et al.18 This indicates 
that DISH consistently correlates well with FISH 
for quantitative results. Our study also showed that 
FISH and DISH had a high level of agreement in 
classifying HER2 gene amplification status. Bland-
Altman plot showed good agreement between 
FISH and DISH. Agreement was less at a higher 
HER2/CEP17 ratio, and DISH tended to under-
estimate the result. This is similar to the findings by 
Mansfield et al.20 Cohen’s Kappa coefficient in our 
study was 0.882. Reports by other studies vary, from 
>0.9 in the study by Horii et al18 in which only 48% 
of cases studied were of the equivocal IHC category, 
to 0.58 by Mansfield et al20 who focused on samples 
enriched for difficult-to-assess HER2 anomalies.
 For our case series, the failure rate of FISH was 
0.96%. This is consistent with failure rates reported 
in the literature that range from <1% to 8.4%.11,17,18,20 
The failure rate for DISH in our case series was 
3.85%, which is slightly higher than the reported 
failure rate of 0% to 2.8% in previous studies.17,18,20 
This may be explained by the fact that most cases in 
our series were of IHC 2+ category, which is the most 
challenging group of cases. It is worth noting that in 
all cases wherein FISH or DISH analysis failed, when 
one test failed, the other gave useful information 
on HER2 gene amplification status. Therefore the 
availability of both FISH and DISH assay allows one 
test to be used as an alternative, when the other fails.
 The number of cases in our study was relatively 
small compared with other published studies,17,18,20 
with only 83 consecutive cases of equivocal IHC 
cases within a given time period. Although it may 
be argued that the further 21 cases added in the 
IHC-positive or -negative category may constitute 
sampling bias, re-analysis of the data excluding these 
cases made no significant difference to the findings. 
Moreover, these 21 cases demonstrated 100% 
concordance between FISH and DISH, supporting 
the robustness of both tests in straightforward cases. 
Abbreviations: DISH = dual-colour in-situ hybridisation; FISH = fluorescence in-situ hybridisation; IHC = immunohistochemistry; 
Non-amp = non-amplified
TABLE 4.  The cases in which two assays showed non-concordance on amplification status
Case No. IHC FISH DISH
HER2/CEP17 
ratio
HER2 per 
nucleus
Amplification 
status
HER2/CEP17 
ratio
HER2 per 
nucleus
Amplification 
status
8 2+ 1.65 4.05 Equivocal 1.38 2.55 Non-amp
13 2+ 1.38 3.25 Non-amp 1.27 4.5 Equivocal
26 2+ 1.35 2.30 Non-amp 1.84 4.15 Equivocal
83 2+ 1.27 1.65 Non-amp 2.85 5.7 Amplified
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Indeed, of the four discordant cases between FISH 
and DISH, three were of the equivocal category by 
FISH or by DISH by the updated ASCO/CAP 2013 
guidelines, but had given concordant non-amplified 
results both by FISH and by DISH using the earlier 
ASCO/CAP 2007 guidelines.
 Another limitation of our study was that 
it was not prospective: only raw data of signal 
enumeration for FISH testing previously performed 
were available. The statistical analysis was based on 
reclassification of cases according to new ASCO/
CAP 2013 guidelines. Although the FISH and DISH 
slides were interpreted by different personnel, 
with the possibility of interobserver variability, the 
concordance between the two assays was very good.
Conclusions
Our study confirms that the determination of HER2 
gene amplification status by DISH correlates well 
with that by FISH. In our laboratory, DISH would 
be a reliable and useful option for HER2 testing in 
breast cancer. Having both FISH and DISH assay 
available for service could help reduce the number 
of failed cases.
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